Table 1.
TTF and ORR with afatinib in patients with NSCLC harboring uncommon mutations.
| TTF | ORR | |||||||
|---|---|---|---|---|---|---|---|---|
| n | EGFR TKI Naïve | n | EGFR TKI Pretreated | n | EGFR TKI Naïve | n | EGFR TKI Pretreated | |
| Overall | 587 | 10.7 (9.7–11.5) | 425 | 4.5 (3.9–5.6) | 506 | 252 (49.8) | 205 | 55 (26.8) |
| Major uncommon mutation | 305 | 12.6 (11.5–15.9) | 117 | 5.3 (3.6–8.4) | 278 | 164 (59.0) | 54 | 16 (29.6) |
| G719X | 194 | 14.2 (11.5–17.0) | 81 | 4.7 (3.0–8.9) | 181 | 111 (61.3) | 39 | 5 (12.8) |
| L861Q | 109 | 11.5 (10.5–13.8) | 45 | 4.4 (2.5–8.1) | 97 | 56 (57.7) | 23 | 9 (39.1) |
| S768I | 61 | 15.9 (11.5–20.5) | 34 | 3.0 (3.0–5.7) | 56 | 40 (71.4) | 16 | 3 (18.8) |
| Compound | 182 | 11.5 (9.5–13.8) | 210 | 4.4 (3.5–5.6) | 155 | 99 (63.9) | 110 | 24 (21.8) |
| + major uncommon | 90 | 16.0 (14.2–20.5) | 38 | 6.0 (3.0–9.9) | 83 | 61 (73.5) | 20 | 5 (25.0) |
| + exon20ins | 11 | 12.5 (3.8–13.1) | 19 | 4.2 (2.0–7.5) | 9 | 5 (55.6) | 10 | 0 |
| + T790M | 48 | 4.7 (3.0–6.5) | 131 | 3.8 (3.0–5.7) | 35 | 11 (31.4) | 62 | 12 (19.4) |
| + others | 33 | 11.5 (9.5–13.8) | 22 | 4.5 (2.7–15.0) | 28 | 22 (78.6) | 18 | 7 (38.9) |
| Exon 20 insertion | 135 | 5.7 (4.8–8.3) | 84 | 4.4 (2.8–7.5) | 114 | 31 (27.2) | 31 | 4 (12.9) |
| T790M | 59 | 4.7 (2.8–6.5) | 149 | 4.0 (3.4–5.6) | 42 | 11 (26.2) | 73 | 13 (17.8) |
| Others | 88 | 10.7 (7.0–12.0) | 75 | 4.5 (3.6–8.1) | 72 | 46 (63.9) | 47 | 22 (46.8) |
| E709X | 15 | 11.4 (3.8–19.3) | 11 | 12.2 (7.0–NE) | 13 | 11 (84.6) | 7 | 6 (85.7) |
| L747X | 18 | 14.7 (9.0–19.8) | 4 | NE (0.5–NE) | 15 | 12 (80.0) | 3 | 2 (66.7) |
EGFR, epidermal growth factor receptor; NE, not evaluable; NSCLC, non-small-cell lung cancer; ORR, objective response rate; TKI, tyrosine kinase inhibitors; TTF, time to treatment failure.